Search
Cynodon dactylon pollen
go.drugbank.com/drugs/DB10351ApprovedIt can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction. … Diagnostic allergenic extracts are primarily indicated for establishing clinical relevance of specific allergens to which the patient has been exposed and the degree of sensitivity the patient has toward
Mixtures: Treatment Set TS329678, Treatment Set TS333938Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnIn a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalChikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus. … In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection.
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] Butyrfentanyl has no current legitimate clinical applications, but anecdotal reports indicate it may occasionally be surfacing on the grey-market as a recreational drug.
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalThis drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnFirst-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
Varlitinib
go.drugbank.com/drugs/DB05944InvestigationalVarlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. … Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.